C-Path Impact

Critical Path Institute (C-Path) has achieved demonstrable results across several scientific and medical industries with significant increases in market valuation. Below are a few metrics that speak to the impact C-Path has made:

Alzheimer’s disease:

• The AD drug market valuation in 2016 was estimated at about $3B, when drugs to prevent the onset of dementia were failing left and right (https://drug-dev.com/market-brief-alzheimers-disease-market-report-2016-2026/#:~:text=ALZHEIMER’S%20DISEASE%20MARKET%20FORECAST,and%20UK)%2C%20and%20Japan).
• We got the regulatory endorsement for the pre-dementia disease progression model in 2018.
• Several companies started adopting this model for their pre-dementia trials.
• With the approvals of aducanumab and lecanemab to delay the onset of dementia in 2022, the 2022 AD drug market valuation sat at $5.1B (https://www.globenewswire.com/news-release/2023/01/24/2594346/28124/en/Global-Alzheimer-s-Drugs-Market-Report-2023-2027-Key-Players-Include-Sanofi-F-Hoffmann-La-Roche-Pfizer-and-Abbott-Laboratories.html).
• The adoption of C-Path’s solutions contributed to the approval of these drugs, and consequently to the approximate 70% increase in market valuation.

Tuberculosis:

• The TB drug market valuation in 2010 was estimated at about $450M, when no new drugs had been approved for about half a century (https://www.tballiance.org/news/estimated-market-tuberculosis-drugs-700-million-2010-first-analysis-market-30-years).
• We developed a host of quantitative solutions for TB drug development.
• Several companies started adopting these solutions, even before full regulatory endorsement (with the direct encouragement of the anti-infectives review division at FDA, as well as the CHMP at EMA).
• With the approvals of bedaquiline (2013), and then the approval of the bedaquiline+pretomanid+linezolid regimen (2017), the 2021 TB drug market valuation sat at almost $2B (https://www.yahoo.com/now/research-report-mycobacterium-tuberculosis-tb-153000884.html).
• The adoption of C-Path’s solutions contributed to the approval of these drugs and regimens, and consequently to the approximate 450% increase in market valuation.

Polycystic kidney disease:

• When we started the PKD Outcomes Consortium, there were no approved therapies to slow or halt the progression of PKD.
• We developed the disease and biomarker progression models that provided the supporting evidence for the qualification of total kidney volume as an enrichment biomarker to optimize patient selection for PKD trials, as well as the designation of total kidney volume as a reasonably likely surrogate marker for PKD trials.
• The PKD field adopted TKV for these uses.
• The approval of tolvaptan (2015) opened the flood gates for a now robust pipeline of novel drugs being developed for PKD, leading to a 2021 PKD drug market valuation of $450M (https://www.databridgemarketresearch.com/reports/global-polycystic-kidney-disease-adpkd-market#:~:text=Data%20Bridge%20Market%20Research%20analyses,period%20of%202022%20to%202029).
• The adoption of C-Path’s solutions contributed to the approval of the first-ever drug to slow or halt PKD progression, leading to the establishment of a solid market that benefits a population in need.